Gamco Investors INC. ET AL lessened its holdings in Chemed Corp. (NYSE:CHE) by 5.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 527,204 shares of the company’s stock after selling 29,280 shares during the period. Gamco Investors INC. ET AL owned about 3.30% of Chemed Corp. worth $106,522,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of CHE. Acrospire Investment Management LLC acquired a new stake in shares of Chemed Corp. in the second quarter worth $120,000. Pacad Investment Ltd. boosted its position in shares of Chemed Corp. by 250.0% in the second quarter. Pacad Investment Ltd. now owns 700 shares of the company’s stock worth $143,000 after buying an additional 500 shares during the period. IFP Advisors Inc boosted its position in shares of Chemed Corp. by 1,504.5% in the third quarter. IFP Advisors Inc now owns 706 shares of the company’s stock worth $143,000 after buying an additional 662 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Chemed Corp. by 12.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock worth $150,000 after buying an additional 83 shares during the period. Finally, MCF Advisors LLC acquired a new stake in shares of Chemed Corp. in the third quarter worth $152,000. 97.29% of the stock is owned by institutional investors and hedge funds.

Several brokerages recently issued reports on CHE. Zacks Investment Research upgraded Chemed Corp. from a “hold” rating to a “buy” rating and set a $251.00 price objective for the company in a report on Thursday. TheStreet upgraded Chemed Corp. from a “c+” rating to an “a-” rating in a report on Friday, October 27th. Royal Bank Of Canada increased their price objective on Chemed Corp. to $232.00 and gave the stock a “sector perform” rating in a report on Tuesday, October 31st. KeyCorp reiterated a “hold” rating on shares of Chemed Corp. in a report on Friday, October 27th. Finally, Oppenheimer Holdings, Inc. increased their price objective on Chemed Corp. from $220.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, October 27th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $236.00.

Shares of Chemed Corp. (CHE) traded down $4.81 during trading hours on Monday, hitting $230.20. The company had a trading volume of 27,965 shares, compared to its average volume of 96,024. The company has a debt-to-equity ratio of 0.15, a current ratio of 0.50 and a quick ratio of 0.48. The firm has a market capitalization of $3,752.17, a PE ratio of 28.94, a price-to-earnings-growth ratio of 4.97 and a beta of 1.14.

Chemed Corp. (NYSE:CHE) last announced its quarterly earnings data on Thursday, October 26th. The company reported $2.15 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.15. Chemed Corp. had a return on equity of 27.69% and a net margin of 4.62%. The business had revenue of $417.40 million during the quarter, compared to analyst estimates of $414.34 million. During the same period last year, the company earned $1.73 earnings per share. Chemed Corp.’s quarterly revenue was up 6.3% compared to the same quarter last year. equities analysts anticipate that Chemed Corp. will post 4.73 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 4th. Shareholders of record on Monday, November 13th will be issued a dividend of $0.28 per share. The ex-dividend date of this dividend is Friday, November 10th. This represents a $1.12 annualized dividend and a yield of 0.49%. Chemed Corp.’s dividend payout ratio (DPR) is currently 24.89%.

In other Chemed Corp. news, CEO Kevin J. Mcnamara sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, October 31st. The stock was sold at an average price of $223.42, for a total transaction of $2,234,200.00. Following the transaction, the chief executive officer now directly owns 170,016 shares in the company, valued at $37,984,974.72. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Spencer S. Lee sold 1,000 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $228.45, for a total value of $228,450.00. Following the transaction, the executive vice president now owns 36,809 shares in the company, valued at $8,409,016.05. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 13,250 shares of company stock worth $2,927,418. Corporate insiders own 4.90% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/chemed-corp-che-stake-lowered-by-gamco-investors-inc-et-al/1683002.html.

About Chemed Corp.

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corp. (NYSE:CHE).

Institutional Ownership by Quarter for Chemed Corp. (NYSE:CHE)

Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.